A Phase Ib/II Multicenter, Open-Label Clinical Trial of SHR-A1811 Injection in Combination With Pyrotinib or Pertuzumab or Adebrelimab or Paclitaxel for Injection (Albumin Bound) in Breast Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
To evaluate the safety, tolerability and efficacy of SHR-A1811 in combination with pyrotinib or pertuzumab or adebrelimab or albumin-bound paclitaxel in patients with breast cancer.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Women aged 18 to 75 (inclusive)
• Breast cancer confirmed by histology or cytology.
• ECOG score is 0 or 1
• An expected survival of ≥ 12 weeks
• At least one measurable lesion according to RECIST v1.1 criteria
• Have adequate renal and hepatic function
• Patients voluntarily joined the study and signed informed consent
Locations
Other Locations
China
Jiangsu Provincial People's Hospital
RECRUITING
Nanjing
Contact Information
Primary
Xiaoxue Pi
Xiaoxue.pi@hengrui.com
0518-82342973
Time Frame
Start Date: 2022-05-23
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 402
Treatments
Experimental: SHR-A1811combined Pyrotinib
Experimental: SHR-A1811Combined Pertuzumab
Experimental: SHR-A1811Combined Adebrelimab
Experimental: SHR-A1811Combined Albumin-bound Paclitaxel
Related Therapeutic Areas
Sponsors
Leads: Jiangsu HengRui Medicine Co., Ltd.